SCHEMBL21611942

SCHEMBL21611942

FC(F)(F)c1cc(SCc2cnc(-c3ccc(Cl)cc3)s2)ccn1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PPARD Q03181 2/20 0.47
▸ CYP2C9 P11712 1/20 0.46
▸ CYP2C19 P33261 1/20 0.46
▸ SMN1; SMN2 Q16637 6/20 0.38
▸ LMNA P02545 4/20 0.38
▸ RAB9A P51151 3/20 0.38
▸ NPC1 O15118 2/20 0.38
▸ TP53 P04637 1/20 0.38
▸ TSHR P16473 1/20 0.38
▸ NFKB1 P19838 1/20 0.38
▸ NFKB2 Q00653 1/20 0.38
▸ RELA Q04206 1/20 0.38
▸ ALDH1A1 P00352 2/20 0.37
▸ L3MBTL1 Q9Y468 3/20 0.36
▸ HPGD P15428 3/20 0.36
▸ MAPT P10636 3/20 0.36
▸ TDP1 Q9NUW8 2/20 0.36
▸ LOXL2 Q9Y4K0 2/20 0.35
▸ ALPG P10696 1/20 0.35
▸ LOX P28300 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21612047 0.84 PPARD (0.48) PPARDCYP2C9CYP2C19SMN1; SMN2LMNA
SCHEMBL21611937 0.79 LOXL2 (0.38) PPARDCYP2C9CYP2C19SMN1; SMN2ALDH1A1
SCHEMBL21614743 0.78 DAO (0.38) SMN1; SMN2LMNARAB9ANPC1ALDH1A1
SCHEMBL21614667 0.77 CYP2C19 (0.68) CYP2C9CYP2C19SMN1; SMN2LMNATP53
SCHEMBL21611981 0.75 PTGS2 (0.53) SMN1; SMN2LMNARAB9ANPC1TSHR
SCHEMBL21611992 0.74 CYP1A2 (0.47) CYP2C9CYP2C19SMN1; SMN2LMNARAB9A
SCHEMBL21611963 0.73 LOXL2 (0.38) CYP2C9CYP2C19LMNARAB9AALDH1A1
SCHEMBL21614746 0.71 LOXL2 (0.35) CYP2C9CYP2C19SMN1; SMN2RAB9ANPC1
SCHEMBL21614744 0.71 HDAC1 (0.36) CYP2C9CYP2C19LOXL2LOX
SCHEMBL15454013 0.69 LOXL2 (0.46) SMN1; SMN2RAB9ANPC1L3MBTL1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210353606-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-11-18 — — US disclosed
EP-3818045-A1 PQSR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2021-05-12 — — EP disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed
WO-2020007938-A1 PqsR INVERSE AGONISTS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2020-01-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210353606-A1 PqsR INVERSE AGONISTS QRFPR, P2RY11, QARS1 PPARD 297/4885CYP2C9 2997/4885CYP2C19 1824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback